Condition: Palliative Care · Pain · Anxiety · Sponsor: University Hospital, Basel, Switzerland
Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects. Objective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an advanced or end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.
This description comes directly from the study's public registry record.
Yasmin Schmid, PD Dr. med. · : +41 61 328 68 47 · yasmin.schmid@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel, Division of Clinical Pharmacology and Toxicology | Basel, Switzerland | Recruiting |
| University Hospital Geneva, Palliative medicine department | Collonge-Bellerive, Switzerland | Recruiting |
| Spital Uster AG, Division of Internal Medicine | Uster, Switzerland | Recruiting |
| University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05883540